Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution

Shu-Wei Chen; Meng-Hua Li; Jian-Liang Liu; Jing-Tao Chen; Jia Wang; Hui Li; Xi-Yuan Li; Ying Zhang; Ming Song; Jia-Xuan Lu; Wen-Kuan Chen

doi:10.1002/lio2.1072

Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution

Laryngoscope Investig Otolaryngol. 2023 May 27;8(3):686-692. doi: 10.1002/lio2.1072. eCollection 2023 Jun.

Authors

Affiliations

¹ Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong China.
² Department of Pediatric Dentistry, Guanghua School of Stomatology, Affiliated Stomatological Hospital Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University Guangzhou Guangdong China.

Abstract

Objectives: To analyze the treatment outcomes and prognostic factors of mucosal melanoma of the head and neck (MMHN) from a single institution.

Methods: From December 1989 to November 2018, 190 patients diagnosed with MMHN were included. Survival analysis was performed using the Kaplan-Meier method for univariate analysis with a log-rank test for significance and Cox regression for multivariate analysis.

Results: With a median follow-up time of 43.5 months, 126 (68.5%) patients died. The median DSS was 35 months. The 3- and 5-year disease-specific survival (DSS) rates were 48.1% and 33.7%, respectively. The median overall survival (OS) was 34 months. The 3- and 5-year OS rates were 47.0% and 32.9%, respectively. In univariate analysis, the T3 stage, received surgery, R0 resection, and combined therapy (surgery+biotherapy/biochemotherapy) were significantly associated with better survival. Multivariable Cox regression analysis revealed that the T4 stage (HR = 1.692; 95% CI, 1.175-2.438; p = .005) and the N1 stage (HR = 1.600; 95% CI, 1.023-2.504; p = .039) were strong prognostic factors for poor survival, and that combined therapy (surgery+biotherapy/biochemotherapy) was a strong prognostic factor for better survival outcome (HR = 0.563; 95% CI, 0.354-0.896; p = .015).

Conclusion: The prognosis of MMHN remains poor. Systemic treatment is warranted to reduce MMHN progression. Surgery combined with biotherapy may improve survival.

Keywords: biotherapy; head and neck; mucosal melanoma; prognosis; survival; treatment.